Waxman Seeks Phenylephrine NDAC Review; Cites Efficacy Concerns

Rep. Henry Waxman (D-Calif.) is calling for an FDA advisory panel to reconsider the efficacy of the nasal decongestant phenylephrine and re-evaluate its status as a monograph ingredient

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

More from Pink Sheet